Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Rational combinations using HDAC inhibitors Bots M; Johnstone RWClin Cancer Res 2009[Jun]; 15 (12): 3970-7In addition to well-characterized genetic abnormalities that lead to cancer onset and progression, it is now recognized that alterations to the epigenome may also play a significant role in oncogenesis. As a result, epigenetic-modulating agents such as histone deacetylase inhibitors (HDACi) have attracted enormous attention as anticancer drugs. In numerous in vitro and preclinical settings, these compounds have shown their vast potential as single agent anticancer therapies, but unfortunately equivalent responses have not always been observed in patients. Given the pleiotropic effects HDACi have on malignant cells, their true therapeutic potential most likely lies in combination with other anticancer drugs. In this review we will focus on the anticancer effects of HDACi when combined with other cancer therapeutics with an emphasis on those combinations based on a strong molecular rationale.|*Antineoplastic Combined Chemotherapy Protocols[MESH]|*Histone Deacetylase Inhibitors[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Apoptosis Regulatory Proteins/metabolism[MESH]|Clinical Trials as Topic[MESH]|Enzyme Inhibitors/*therapeutic use[MESH]|Humans[MESH]|Myelodysplastic Syndromes/*drug therapy/genetics[MESH]|Neoplasms/*drug therapy/genetics[MESH] |